These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38914753)

  • 1. Type I interferon pathway in pediatric systemic lupus erythematosus.
    Zhou Y; Song HM
    World J Pediatr; 2024 Jul; 20(7):653-668. PubMed ID: 38914753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
    Gallucci S; Meka S; Gamero AM
    Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus.
    Kwok SK; Lee JY; Park SH; Cho ML; Min SY; Park SH; Kim HY; Cho YG
    Arthritis Res Ther; 2008; 10(2):R29. PubMed ID: 18321389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
    Garcia-Romo GS; Caielli S; Vega B; Connolly J; Allantaz F; Xu Z; Punaro M; Baisch J; Guiducci C; Coffman RL; Barrat FJ; Banchereau J; Pascual V
    Sci Transl Med; 2011 Mar; 3(73):73ra20. PubMed ID: 21389264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
    Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
    Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus Erythematosus.
    An J; Durcan L; Karr RM; Briggs TA; Rice GI; Teal TH; Woodward JJ; Elkon KB
    Arthritis Rheumatol; 2017 Apr; 69(4):800-807. PubMed ID: 27863149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.
    Sakata K; Nakayamada S; Miyazaki Y; Kubo S; Ishii A; Nakano K; Tanaka Y
    Front Immunol; 2018; 9():1957. PubMed ID: 30210502
    [No Abstract]   [Full Text] [Related]  

  • 13. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.
    Kato Y; Park J; Takamatsu H; Konaka H; Aoki W; Aburaya S; Ueda M; Nishide M; Koyama S; Hayama Y; Kinehara Y; Hirano T; Shima Y; Narazaki M; Kumanogoh A
    Ann Rheum Dis; 2018 Oct; 77(10):1507-1515. PubMed ID: 29945921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
    Greth W; Robbie GJ; Brohawn P; Hultquist M; Yao B
    Immunotherapy; 2017 Jan; 9(1):57-70. PubMed ID: 28000522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
    Wang Y; Ewart D; Crabtree JN; Yamamoto A; Baechler EC; Fazeli P; Peterson EJ
    Arthritis Rheumatol; 2015 Sep; 67(9):2403-14. PubMed ID: 26018863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
    Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
    Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo PACSIN1 Gene Variant Found in Childhood Lupus and a Role for PACSIN1/TRAF4 Complex in Toll-like Receptor 7 Activation.
    Xie C; Zhou H; Athanasopoulos V; Shen Q; Zhang Y; Meng X; Burgio G; Arsov T; Lungu AC; Zhang P; Qin Y; Ma J; Wu X; Jiang X; Ding H; Meng Y; Shen N; He Y; Vinuesa CG
    Arthritis Rheumatol; 2023 Jun; 75(6):1058-1071. PubMed ID: 36622335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus.
    Li Y; Lee PY; Kellner ES; Paulus M; Switanek J; Xu Y; Zhuang H; Sobel ES; Segal MS; Satoh M; Reeves WH
    Arthritis Res Ther; 2010; 12(3):R90. PubMed ID: 20478071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.